Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00426556

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00426556. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer. Phase II: will assess the efficacy and safety of the 10mg daily dose of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.

Study identification

NCT ID
NCT00426556
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
88 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2007 (Type not available)
Primary completion
Mar 2014 (Actual)
Completion
Mar 2014 (Actual)
Last update posted
Dec 28, 2015

2007 – 2014

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Wilshire Oncology Medical Group La Verne *see Various Departments* California — —
Compassionate Cancer Care Medical Group Dept.ofCCCMG Fountain Valley California 92708 —
Loma Linda University Dept.ofLomaLindaCancerCent(3) Loma Linda California 92354 —
University of California at Los Angeles Dept.of UCLA Dept.ofMed. Los Angeles California 90095 —
Florida Cancer Research Institute Davie Florida 33328 —
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) Atlanta Georgia 30322 —
North Shore University Health System Evanston Illinois 60201 —
Peninsula Regional Medical Center Deptof Oncology and Hematology Salisbury Maryland 21801 —
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CRAD001J2101 St Louis Missouri 63110 —
Cancer Centers of the Carolinas CC of C -Eastside Greenville South Carolina 29605 —
Sammons Cancer Center - Texas Oncology Dallas Texas 78246 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00426556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 28, 2015 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.